BR112012023971A2 - composto, composição farmacêutica, e, uso de um composto. - Google Patents
composto, composição farmacêutica, e, uso de um composto.Info
- Publication number
- BR112012023971A2 BR112012023971A2 BR112012023971A BR112012023971A BR112012023971A2 BR 112012023971 A2 BR112012023971 A2 BR 112012023971A2 BR 112012023971 A BR112012023971 A BR 112012023971A BR 112012023971 A BR112012023971 A BR 112012023971A BR 112012023971 A2 BR112012023971 A2 BR 112012023971A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- faah
- disease
- pharmaceutical composition
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32669510P | 2010-04-22 | 2010-04-22 | |
| PCT/US2011/032842 WO2011133447A1 (en) | 2010-04-22 | 2011-04-18 | Oxazole derivatives useful as modulators of faah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012023971A2 true BR112012023971A2 (pt) | 2016-11-29 |
Family
ID=44834467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012023971A BR112012023971A2 (pt) | 2010-04-22 | 2011-04-18 | composto, composição farmacêutica, e, uso de um composto. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9073879B2 (enExample) |
| EP (1) | EP2593102B1 (enExample) |
| JP (1) | JP5856606B2 (enExample) |
| CN (1) | CN103153307A (enExample) |
| AU (1) | AU2011242961B2 (enExample) |
| BR (1) | BR112012023971A2 (enExample) |
| CA (1) | CA2794724A1 (enExample) |
| WO (1) | WO2011133447A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| MX2014015265A (es) | 2012-06-14 | 2015-08-12 | Basf Se | Metodos plaguicidas que utilizan compuestos de 3-piridiltiazol sustituido y derivados para combatir plagas de animales. |
| MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| SG10201704327RA (en) | 2013-10-14 | 2017-06-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| EP3725788A1 (en) | 2019-04-15 | 2020-10-21 | Bayer AG | Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides |
| CN114502545B (zh) | 2019-07-23 | 2024-06-28 | 拜耳公司 | 作为农药的新的杂芳基-三唑化合物 |
| TW202136248A (zh) | 2019-11-25 | 2021-10-01 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
| US20230148601A1 (en) | 2020-02-18 | 2023-05-18 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
| TWI891782B (zh) | 2020-05-06 | 2025-08-01 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基三唑化合物 |
| KR20240051198A (ko) | 2021-08-25 | 2024-04-19 | 바이엘 악티엔게젤샤프트 | 농약제로서 신규 피라지닐-트리아졸 화합물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268817B2 (en) * | 2006-09-08 | 2012-09-18 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| WO2008100977A2 (en) * | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| AU2008260496A1 (en) * | 2007-05-31 | 2008-12-11 | The Scripps Research Institute | Tricyclic inhibitors of fatty acid amide hydrolase |
| WO2009154785A2 (en) | 2008-06-19 | 2009-12-23 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
-
2011
- 2011-04-18 WO PCT/US2011/032842 patent/WO2011133447A1/en not_active Ceased
- 2011-04-18 AU AU2011242961A patent/AU2011242961B2/en not_active Ceased
- 2011-04-18 JP JP2013506203A patent/JP5856606B2/ja not_active Expired - Fee Related
- 2011-04-18 BR BR112012023971A patent/BR112012023971A2/pt not_active IP Right Cessation
- 2011-04-18 US US13/635,286 patent/US9073879B2/en active Active
- 2011-04-18 CA CA2794724A patent/CA2794724A1/en not_active Abandoned
- 2011-04-18 EP EP11772492.2A patent/EP2593102B1/en active Active
- 2011-04-18 CN CN201180019926XA patent/CN103153307A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011242961B2 (en) | 2015-09-24 |
| US20130012526A1 (en) | 2013-01-10 |
| JP2013525356A (ja) | 2013-06-20 |
| EP2593102A1 (en) | 2013-05-22 |
| EP2593102B1 (en) | 2017-06-07 |
| WO2011133447A1 (en) | 2011-10-27 |
| CN103153307A (zh) | 2013-06-12 |
| US9073879B2 (en) | 2015-07-07 |
| JP5856606B2 (ja) | 2016-02-10 |
| EP2593102A4 (en) | 2013-12-04 |
| AU2011242961A1 (en) | 2012-09-27 |
| CA2794724A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023971A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BR112012023974A2 (pt) | composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. | |
| BR112012028055A2 (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| MX2012008801A (es) | Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones. | |
| NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
| BRPI0717596B8 (pt) | compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| EA201171283A1 (ru) | Новая технология изготовления мелоксикама | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| UA99582C2 (ru) | Ветеринарная фармацевтическая композиция и способ (варианты) профилактики и лечения заболеваний жкт и интоксикаций разной этиологии у животных | |
| EA200900330A1 (ru) | Аналоги 2-феноксипиримидинона | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| BR112012003390A2 (pt) | método de radioiodação de uma unidade de marcação biológica, composto, composição radiofarmacêutica, método de preparação do composto, usos de um compsto, e de um aparelho sintetizador automatizado, cassete estéril, de uso único, e, métodos para gerar uma imagem de um corpo de animal ou de humano, e para monitorar o efeiro de tratamento de um corpo de aninmal ou de humano com uma droga. | |
| EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| UA112418C2 (uk) | Терапевтичний болезаспокійливий засіб | |
| BR112013002945A2 (pt) | composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B08F | Application fees: dismissal - article 86 of industrial property law | ||
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |